Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831721 | 0.93 | HRH3 (0.59) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| SCHEMBL2201741 | 0.92 | RORC (0.48) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| SCHEMBL2200787 | 0.90 | MAOA (0.49) | RORC | |
| SCHEMBL2204043 | 0.90 | RORC (0.49) | RORCHRH3CYP2A6 | |
| SCHEMBL19088665 | 0.89 | HRH3 (0.64) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| SCHEMBL1637428 | 0.89 | SIGMAR1 (0.48) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| SCHEMBL10990552 | 0.88 | TSHR (0.57) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL2205187 | 0.87 | SIGMAR1 (0.47) | RORCHRH3CYP2A6TSHRHSD17B10 | |
| SCHEMBL2202929 | 0.85 | POLB (0.62) | RORCHRH3CYP2A6MAPT | |
| SCHEMBL2200366 | 0.85 | RORC (0.46) | RORCHRH3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | RORC 4375/4885HRH3 132/4885CYP2A6 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.